Publications
Found 3 results
Filters: Author is S. Ghavami [Clear All Filters]
“R620W functional polymorphism of protein tyrosine phosphatase non-receptor type 22 is not associated with pulmonary tuberculosis in Zahedan, southeast Iran”, vol. 11, pp. 1075-1081, 2012.
, Ban Y, Tozaki T, Taniyama M and Tomita M (2005). The codon 620 single nucleotide polymorphism of the protein tyrosine phosphatase-22 gene does not contribute to autoimmune thyroid disease susceptibility in the Japanese. Thyroid 15: 1115-1118.
http://dx.doi.org/10.1089/thy.2005.15.1115
PMid:16279843
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, et al. (2004). A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75: 330-337.
http://dx.doi.org/10.1086/422827
PMid:15208781
Bellamy R, Beyers N, McAdam KP, Ruwende C, et al. (2000). Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc. Natl. Acad. Sci. U. S. A. 97: 8005-8009.
http://dx.doi.org/10.1073/pnas.140201897
PMid:10859364
Bottini N, Musumeci L, Alonso A, Rahmouni S, et al. (2004). A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36: 337-338.
http://dx.doi.org/10.1038/ng1323
PMid:15004560
Bravo MJ, Colmenero JD, Queipo-Ortuno MI, Morata P, et al. (2009). PTPN22 C1858T polymorphism and human brucellosis. Scand J. Infect. Dis. 41: 109-112.
http://dx.doi.org/10.1080/00365540802641864
PMid:19107641
Cervino AC, Lakiss S, Sow O, Bellamy R, et al. (2002). Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families. Hum. Mol. Genet. 11: 1599-1603.
http://dx.doi.org/10.1093/hmg/11.14.1599
PMid:12075004
Chabchoub G, Maalej A, Petit-Teixeira E, Glikmans E, et al. (2006). Polymorphisms in the protein tyrosine phosphatase (PTPN22) gene is not associated with autoimmune thyroid in a large affected Tunisian family. Clin. Immunol. 120: 235-236.
http://dx.doi.org/10.1016/j.clim.2006.04.565
PMid:16765647
Chabchoub G, Teixiera EP, Maalej A, Ben HM, et al. (2009). The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population. Ann. Hum. Biol. 36: 342-349.
http://dx.doi.org/10.1080/03014460902817968
PMid:19343596
Chelala C, Duchatelet S, Joffret ML, Bergholdt R, et al. (2007). PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits. Diabetes 56: 522-526.
http://dx.doi.org/10.2337/db06-0942
PMid:17259401
Cohen S, Dadi H, Shaoul E, Sharfe N, et al. (1999). Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 93: 2013-2024.
Comstock GW (1978). Tuberculosis in twins: a re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 117: 621-624.
PMid:565607
Douroudis K, Prans E, Haller K, Nemvalts V, et al. (2008). Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens 72: 425-430.
http://dx.doi.org/10.1111/j.1399-0039.2008.01115.x
PMid:18764813
Gomez LM, Anaya JM, Gonzalez CI, Pineda-Tamayo R, et al. (2005a). PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases. Genes Immun. 6: 628-631.
http://dx.doi.org/10.1038/sj.gene.6364261
PMid:16163373
Gomez LM, Anaya JM and Martin J (2005b). Genetic influence of PTPN22 R620W polymorphism in tuberculosis. Hum. Immunol. 66: 1242-1247.
http://dx.doi.org/10.1016/j.humimm.2005.11.008
PMid:16690411
Guide SV and Holland SM (2002). Host susceptibility factors in mycobacterial infection. Genetics and body morphotype. Infect. Dis. Clin. North Am. 16: 163-186.
http://dx.doi.org/10.1016/S0891-5520(03)00051-5
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, et al. (2010a). Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet. Mol. Res. 9: 333-339.
http://dx.doi.org/10.4238/vol9-1gmr728
PMid:20198589
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, et al. (2010b). The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet. Mol. Res. 9: 1735-1741.
http://dx.doi.org/10.4238/vol9-3gmr893
PMid:20812194
Hashemi M, Hoseini H, Yaghmaei P, Moazeni-Roodi A, et al. (2011a). Association of polymorphisms in glutamate-cysteine ligase catalytic subunit and microsomal triglyceride transfer protein genes with nonalcoholic fatty liver disease. DNA Cell Biol. 30: 569-575.
http://dx.doi.org/10.1089/dna.2010.1162
PMid:21438662
Hashemi M, Sharifi-Mood B, Nezamdoost M, Moazeni-Roodi A, et al. (2011b). Functional polymorphism of interferon-gamma (IFN-gamma) gene +874T/A polymorphism is associated with pulmonary tuberculosis in Zahedan, Southeast Iran. Prague Med. Rep. 112: 38-43.
PMid:21470497
Hermiston ML, Xu Z, Majeti R and Weiss A (2002). Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J. Clin. Invest. 109: 9-14.
PMid:11781344 PMCid:150828
Hill RJ, Zozulya S, Lu YL, Ward K, et al. (2002). The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp. Hematol. 30: 237-244.
http://dx.doi.org/10.1016/S0301-472X(01)00794-9
Hinks A, Worthington J and Thomson W (2006). The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. Rheumatology 45: 365-368.
http://dx.doi.org/10.1093/rheumatology/kel005
PMid:16418195
Ikegami H, Kawabata Y, Noso S, Fujisawa T, et al. (2007). Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res. Clin. Pract. 77 (Suppl 1): S116-S121.
http://dx.doi.org/10.1016/j.diabres.2007.01.044
PMid:17452059
Jagiello P, Aries P, Arning L, Wagenleiter SE, et al. (2005). The PTPN22 620W allele is a risk factor for Wegener’s granulomatosis. Arthritis Rheum. 52: 4039-4043.
http://dx.doi.org/10.1002/art.21487
Lamsyah H, Rueda B, Baassi L, Elaouad R, et al. (2009). Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population. Tissue Antigens 74: 228-232.
http://dx.doi.org/10.1111/j.1399-0039.2009.01304.x
PMid:19563523
Lee YH, Rho YH, Choi SJ, Ji JD, et al. (2007). The PTPN22 C1858T functional polymorphism and autoimmune diseases - a meta-analysis. Rheumatology 46: 49-56.
http://dx.doi.org/10.1093/rheumatology/kel170
PMid:16760194
Mori M, Yamada R, Kobayashi K, Kawaida R, et al. (2005). Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J. Hum. Genet. 50: 264-266.
http://dx.doi.org/10.1007/s10038-005-0246-8
PMid:15883854
Mustelin T, Brockdorff J, Rudbeck L, Gjorloff-Wingren A, et al. (1999). The next wave: protein tyrosine phosphatases enter T cell antigen receptor signalling. Cell Signal. 11: 637-650.
http://dx.doi.org/10.1016/S0898-6568(99)00016-9
Mustelin T, Abraham RT, Rudd CE, Alonso A, et al. (2002). Protein tyrosine phosphorylation in T cell signaling. Front Biosci. 7: d918-d969.
http://dx.doi.org/10.2741/musteli1
PMid:11897562
Naderi M, Hashemi M, Kouhpayeh H and Ahmadi R (2009). The status of serum procalcitonin in pulmonary tuberculosis and nontuberculosis pulmonary disease. J. Pak. Med. Assoc. 59: 647-648.
PMid:19750868
Naderi M, Hashemi M, Mehdizadeh A and Mehrabifar H (2010). Serum adenosine deaminase activity and total antioxidant capacity of plasma in pulmonary tuberculosis and non-tuberculosis pulmonary disease. Turk. J. Med. Sci. 40: 701-706.
North RJ and Jung YJ (2004). Immunity to tuberculosis. Annu. Rev. Immunol. 22: 599-623.
http://dx.doi.org/10.1146/annurev.immunol.22.012703.104635
PMid:15032590
Orozco G, Sanchez E, Gonzalez-Gay MA, Lopez-Nevot MA, et al. (2005). Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 52: 219-224.
http://dx.doi.org/10.1002/art.20771
Porter JD and McAdam KP (1994). The re-emergence of tuberculosis. Annu. Rev. Public Health 15: 303-323.
http://dx.doi.org/10.1146/annurev.pu.15.050194.001511
PMid:8054087
Qu HQ, Fisher-Hoch SP and McCormick JB (2011). Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases. Int. J. Infect. Dis. 15: e305-e313.
http://dx.doi.org/10.1016/j.ijid.2011.01.004
PMid:21330176 PMCid:3078969
Reddy MV, Johansson M, Sturfelt G, Jonsen A, et al. (2005). The R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1. Genes Immun. 6: 658-662.
PMid:16052172
Seldin MF, Shigeta R, Laiho K, Li H, et al. (2005). Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis. Genes Immun. 6: 720-722.
PMid:16107870
Veillette A, Latour S and Davidson D (2002). Negative regulation of immunoreceptor signaling. Annu. Rev. Immunol. 20: 669-707.
http://dx.doi.org/10.1146/annurev.immunol.20.081501.130710
PMid:11861615
Wipff J, Allanore Y, Kahan A, Meyer O, et al. (2006). Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population. Ann. Rheum. Dis. 65: 1230-1232.
http://dx.doi.org/10.1136/ard.2005.048181
PMid:16464986 PMCid:1798267
Zhang ZH, Chen F, Zhang XL, Jin Y, et al. (2008). PTPN22 allele polymorphisms in 15 Chinese populations. Int. J. Immunogenet. 35: 433-437.
http://dx.doi.org/10.1111/j.1744-313X.2008.00803.x
PMid:19046301
“The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis”, vol. 9, pp. 1735-1741, 2010.
, Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
http://dx.doi.org/10.1002/art.1780310302
PMid:3358796
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, et al. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
http://dx.doi.org/10.1172/JCI1649
PMid:9541487 PMCid:508738
Aviram M, Hardak E, Vaya J, Mahmood S, et al. (2000). Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517.
http://dx.doi.org/10.1161/01.CIR.101.21.2510
PMid:10831526
Baskol G, Demir H, Baskol M, Kilic E, et al. (2005). Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38: 951-955.
http://dx.doi.org/10.1016/j.clinbiochem.2005.06.010
PMid:16055108
Bauerova K and Bezek A (1999). Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen. Physiol. Biophys. 18 (Spec No.): 15-20.
Blatter MC, James RW, Messmer S, Barja F, et al. (1993). Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
http://dx.doi.org/10.1111/j.1432-1033.1993.tb17620.x
PMid:8382160
Deighton CM and Walker DJ (1991). The familial nature of rheumatoid arthritis. Ann. Rheum. Dis. 50: 62-65.
http://dx.doi.org/10.1136/ard.50.1.62
PMid:1994873 PMCid:1004331
Feingold KR, Memon RA, Moser AH and Grunfeld C (1998). Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307-315.
http://dx.doi.org/10.1016/S0021-9150(98)00084-7
Gambhir JK, Lali P and Jain AK (1997). Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin. Biochem. 30: 351-355.
http://dx.doi.org/10.1016/S0009-9120(96)00007-0
Gan KN, Smolen A, Eckerson HW and La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19: 100-106.
PMid:1673382
Garin MC, James RW, Dussoix P, Blanche H, et al. (1997). Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
http://dx.doi.org/10.1172/JCI119134
PMid:9011577 PMCid:507768
Griffiths HR and Lunec J (1996). The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett. 388: 161-164.
http://dx.doi.org/10.1016/0014-5793(96)00542-X
Halliwell B (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.
http://dx.doi.org/10.1016/S0140-6736(94)92211-X
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, et al. (2010). Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet. Mol. Res. 9: 333-339.
http://dx.doi.org/10.4238/vol9-1gmr728
PMid:20198589
Humbert R, Adler DA, Disteche CM, Hassett C, et al. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
http://dx.doi.org/10.1038/ng0193-73
PMid:8098250
Isik A, Koca SS, Ustundag B, Celik H, et al. (2007). Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin. Rheumatol. 26: 342-348.
http://dx.doi.org/10.1007/s10067-006-0300-8
PMid:16642406
Jaswal S, Mehta HC, Sood AK and Kaur J (2003). Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin. Chim. Acta 338: 123-129.
http://dx.doi.org/10.1016/j.cccn.2003.08.011
PMid:14637276
Leviev I and James RW (2000). Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521.
http://dx.doi.org/10.1161/01.ATV.20.2.516
PMid:10669651
Leviev I, Negro F and James RW (1997). Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17: 2935-2939.
http://dx.doi.org/10.1161/01.ATV.17.11.2935
PMid:9409279
Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423: 57-60.
http://dx.doi.org/10.1016/S0014-5793(98)00064-7
Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76.
http://dx.doi.org/10.1097/00041433-199604000-00004
PMid:8743898
Maury CP, Junge W and Teppo AM (1984). Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J. Lab. Clin. Med. 104: 761-766.
PMid:6092501
McKeown MJ, Hall ND and Corvalan JR (1984). Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin. Exp. Immunol. 56: 607-613.
PMid:6744663 PMCid:1536001
Miesel R, Murphy MP and Kroger H (1996). Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic. Res. 25: 161-169.
http://dx.doi.org/10.3109/10715769609149921
PMid:8885334
Nurcombe HL, Bucknall RC and Edwards SW (1991). Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann. Rheum. Dis. 50: 237-242.
http://dx.doi.org/10.1136/ard.50.4.237
PMid:1851410 PMCid:1004393
Popa C, van Tits LJ, Barrera P, Lemmers HL, et al. (2009). Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68: 868-872.
http://dx.doi.org/10.1136/ard.2008.092171
PMid:18635596
Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507.
http://dx.doi.org/10.1006/geno.1996.0225
PMid:8661009
Ridderstad A, Abedi-Valugerdi M and Moller E (1991). Cytokines in rheumatoid arthritis. Ann. Med. 23: 219-223.
http://dx.doi.org/10.3109/07853899109148051
PMid:1930911
Rozenberg O, Rosenblat M, Coleman R, Shih DM, et al. (2003). Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
http://dx.doi.org/10.1016/S0891-5849(02)01429-6
Sattar N, McCarey DW, Capell H and McInnes IB (2003). Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963.
http://dx.doi.org/10.1161/01.CIR.0000099844.31524.05
PMid:14676136
Shih DM, Gu L, Xia YR, Navab M, et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
http://dx.doi.org/10.1038/28406
PMid:9685159
Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, et al. (2003). Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72: 2877-2885.
http://dx.doi.org/10.1016/S0024-3205(03)00195-4
Ye S, Dhillon S, Ke X, Collins AR, et al. (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29: E88.
http://dx.doi.org/10.1093/nar/29.17.e88
PMid:11522844 PMCid:55900
Zwerina J, Redlich K, Schett G and Smolen JS (2005). Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. N. Y. Acad. Sci. 1051: 716-729.
http://dx.doi.org/10.1196/annals.1361.116
PMid:16127012
“Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran”, vol. 9, pp. 333-339, 2010.
, Agrawal S, Tripathi G, Prajnya R, Sinha N, et al. (2009). Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J. Med. Sci. 63: 335-344.
http://dx.doi.org/10.4103/0019-5359.55884
PMid:19770524
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
http://dx.doi.org/10.1002/art.1780310302
PMid:3358796
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, et al. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
http://dx.doi.org/10.1172/JCI1649
PMid:9541487 PMCid:508738
Aviram M, Hardak E, Vaya J, Mahmood S, et al. (2000). Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517.
http://dx.doi.org/10.1161/01.CIR.101.21.2510
PMid:10831526
Baskol G, Demir H, Baskol M, Kilic E, et al. (2005). Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38: 951-955.
http://dx.doi.org/10.1016/j.clinbiochem.2005.06.010
PMid:16055108
Bauerova K and Bezek A (1999). Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen. Physiol. Biophys. 18 (Spec No.): 15-20.
Blatter MC, James RW, Messmer S, Barja F, et al. (1993). Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
http://dx.doi.org/10.1111/j.1432-1033.1993.tb17620.x
PMid:8382160
Deighton CM and Walker DJ (1991). The familial nature of rheumatoid arthritis. Ann. Rheum. Dis. 50: 62-65.
http://dx.doi.org/10.1136/ard.50.1.62
PMid:1994873 PMCid:1004331
Feingold KR, Memon RA, Moser AH and Grunfeld C (1998). Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307-315.
http://dx.doi.org/10.1016/S0021-9150(98)00084-7
Gambhir JK, Lali P and Jain AK (1997). Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin. Biochem. 30: 351-355.
http://dx.doi.org/10.1016/S0009-9120(96)00007-0
Gan KN, Smolen A, Eckerson HW and La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19: 100-106.
PMid:1673382
Garin MC, James RW, Dussoix P, Blanche H, et al. (1997). Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
http://dx.doi.org/10.1172/JCI119134
PMid:9011577 PMCid:507768
Griffiths HR and Lunec J (1996). The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett. 388: 161-164.
http://dx.doi.org/10.1016/0014-5793(96)00542-X
Halliwell B (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.
http://dx.doi.org/10.1016/S0140-6736(94)92211-X
Humbert R, Adler DA, Disteche CM, Hassett C, et al. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
http://dx.doi.org/10.1038/ng0193-73
PMid:8098250
Isik A, Koca SS, Ustundag B, Celik H, et al. (2007). Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin. Rheumatol. 26: 342-348.
http://dx.doi.org/10.1007/s10067-006-0300-8
PMid:16642406
Jaswal S, Mehta HC, Sood AK and Kaur J (2003). Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin. Chim. Acta 338: 123-129.
http://dx.doi.org/10.1016/j.cccn.2003.08.011
PMid:14637276
Leduc V and Poirier J (2008). Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener. Dis. 5: 225-227.
http://dx.doi.org/10.1159/000113709
PMid:18322397
Leduc V, Theroux L, Dea D, Robitaille Y, et al. (2009). Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci. 30: 1823-1830.
http://dx.doi.org/10.1111/j.1460-9568.2009.06983.x
PMid:19863653
Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423: 57-60.
http://dx.doi.org/10.1016/S0014-5793(98)00064-7
Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76.
http://dx.doi.org/10.1097/00041433-199604000-00004
PMid:8743898
Maury CP, Junge W and Teppo AM (1984). Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J. Lab. Clin. Med. 104: 761-766.
PMid:6092501
McKeown MJ, Hall ND and Corvalan JR (1984). Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin. Exp. Immunol. 56: 607-613.
PMid:6744663 PMCid:1536001
Miesel R, Murphy MP and Kroger H (1996). Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic. Res. 25: 161-169.
http://dx.doi.org/10.3109/10715769609149921
PMid:8885334
Newton CR, Graham A, Heptinstall LE, Powell SJ, et al. (1989). Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17: 2503-2516.
http://dx.doi.org/10.1093/nar/17.7.2503
PMid:2785681 PMCid:317639
Nurcombe HL, Bucknall RC and Edwards SW (1991). Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann. Rheum. Dis. 50: 237-242.
http://dx.doi.org/10.1136/ard.50.4.237
PMid:1851410 PMCid:1004393
Popa C, van Tits LJ, Barrera P, Lemmers HL, et al. (2009). Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68: 868-872.
http://dx.doi.org/10.1136/ard.2008.092171
PMid:18635596
Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507.
http://dx.doi.org/10.1006/geno.1996.0225
PMid:8661009
Rozenberg O, Rosenblat M, Coleman R, Shih DM, et al. (2003). Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
http://dx.doi.org/10.1016/S0891-5849(02)01429-6
Saremi MA, Saremi M and Tavallaei M (2008). Rapid genomic DNA extraction (RGDE). Forensic Sci. Int. Genet. Suppl. Ser. 1: 63-65.
Sattar N, McCarey DW, Capell H and McInnes IB (2003). Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963.
http://dx.doi.org/10.1161/01.CIR.0000099844.31524.05
PMid:14676136
Shih DM, Gu L, Xia YR, Navab M, et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
http://dx.doi.org/10.1038/28406
PMid:9685159
Sidoti A, Antognelli C, Rinaldi C, D'Angelo R, et al. (2007). Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult. Scler. 13: 446-453.
PMid:17463067
Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, et al. (2003). Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72: 2877-2885.
http://dx.doi.org/10.1016/S0024-3205(03)00195-4
Ye S, Dhillon S, Ke X, Collins AR, et al. (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29: E88.
http://dx.doi.org/10.1093/nar/29.17.e88
PMid:11522844 PMCid:55900